TargetBeta
IL2
interleukin 2 · also IL-2, TCGF · Interleukins
7 programs in company-led studies act on IL2, from 5 companies: 2 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| daromunrule | Philogen | phase 3 | 66 running | – | NCIt |
| darleukinrule | Philogen | phase 3 | 95 running | – | NCIt |
| Daxokafusp Alfa | Sanofi | phase 2 | 22 running | IL15, PDCD1 | a judged reading |
| SAR444336 | Sanofi | phase 2 | 21 running | – | the company's pipeline |
| Anti-PD-1/IL-2 Fusion Protein TEV-56278 | Teva Pharmaceutical Industries | phase 1 | 22 running | PDCD1 | the company's pipeline |
| IL-2 Mutein/Fc Fusion Protein HM16390rule | Hanmi Pharmaceutical | phase 1 | 11 running | – | NCIt |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | Outpace Bio | phase 1 | 10 running | EGFR, MSLN | NCIt |
Conditions their studies are in
- Carcinoma, Basal Cell, 2 programs
- Melanoma, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Carcinoma, Renal Cell, 1 program
- Colitis, Microscopic, 1 program
- Colorectal Neoplasms, 1 program
- Ovarian Neoplasms, 1 program
- Pancreatic Neoplasms, 1 program
- Stomach Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 19, 2027Daxokafusp Alfa · Sanofi · phase 2 · NCT05584670
- Apr 8, 2027SAR444336 · Sanofi · phase 2 · NCT07156175
- Dec 2027daromun · Philogen · phase 3 · NCT03567889
- Jul 2028darleukin · Philogen · phase 3 · NCT06284590
- May 26, 2029Anti-PD-1/IL-2 Fusion Protein TEV-56278 · Teva Pharmaceutical Industries · phase 1 · NCT06480552
- Jul 2031IL-2 Mutein/Fc Fusion Protein HM16390 · Hanmi Pharmaceutical · phase 1 · NCT06724016
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.